RION, a commercial and clinical-stage regenerative medicine company pioneering platelet-derived exosomes for both human and animal health applications, has announced a collaboration with Lonza, one of the world’s largest contract development and manufacturing organizations (CDMOs), to provide cGMP manufacturing and technical support for commercial scale production of its Purified Exosome Product™ (PEP™) drug substance for late phase clinical supply and beyond.